Evidence map›Paper›PMID 37697716›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2024

Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease.

Emmanouil Mavrogeorgis, Tianlin He, Harald Mischak, Agnieszka Latosinska, Antonia Vlahou, Joost P Schanstra, Lorenzo Catanese, Kerstin Amann, Tobias B Huber, Joachim Beige and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. [Histology and more-modern nephropathology].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Emmanouil MavrogeorgisMosaiques Diagnostics GmbH, Hannover, Germany.ORCID 0009-0005-1726-0241
Tianlin HeMosaiques Diagnostics GmbH, Hannover, Germany.ORCID 0000-0001-7806-4846
Harald MischakMosaiques Diagnostics GmbH, Hannover, Germany.ORCID 0000-0003-0323-0306
Agnieszka LatosinskaMosaiques Diagnostics GmbH, Hannover, Germany.ORCID 0000-0001-8917-2412
Antonia VlahouCenter of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.ORCID 0000-0003-3284-5713
Joost P SchanstraInstitut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institute of Cardiovascular and Metabolic Disease, Toulouse, France.ORCID 0000-0002-7471-372X
Lorenzo CataneseDepartment of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.ORCID 0000-0002-9933-8364
Kerstin AmannDepartment of Nephropathology, Institute of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-6116-8315
Tobias B HuberIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7175-5062
Joachim BeigeDepartment of Infectious Diseases/Tropical Medicine, Nephrology/KfH Renal Unit and Rheumatology, St Georg Hospital Leipzig, Leipzig, Germany.ORCID 0000-0002-1907-825X
Harald D RupprechtDepartment of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.ORCID 0000-0001-5761-2911
Justyna SiwyMosaiques Diagnostics GmbH, Hannover, Germany.ORCID 0000-0003-1407-2534
Mosaiques Diagnostics and Therapeutics (Germany) · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEBiomedical Research Foundation of the Academy of Athens · GRKlinikum St. Georg · DEUniversität Hamburg · DEUniversitätsklinikum Aachen · DEUniversité Toulouse III - Paul Sabatier · FR

Funding

COST CA21165European Commission 860329Federal Ministry of Education and Research 01EK2105A-EGerman Research Foundation 322900939
6 · The paper itself

Abstract

background and hypothesisSpecific urinary peptides hold information on disease pathophysiology, which, in combination with artificial intelligence, could enable non-invasive assessment of chronic kidney disease (CKD) aetiology. Existing approaches are generally specific for the diagnosis of single aetiologies. We present the development of models able to simultaneously distinguish and spatially visualize multiple CKD aetiologies.

methodsThe urinary peptide data of 1850 healthy control (HC) and CKD [diabetic kidney disease (DKD), immunoglobulin A nephropathy (IgAN) and vasculitis] participants were extracted from the Human Urinary Proteome Database. Uniform manifold approximation and projection (UMAP) coupled to a support vector machine algorithm was used to generate multi-peptide models to perform binary (DKD, HC) and multiclass (DKD, HC, IgAN, vasculitis) classifications. This pipeline was compared with the current state-of-the-art single-aetiology CKD urinary peptide models.

resultsIn an independent test set, the developed models achieved 90.35% and 70.13% overall predictive accuracies, respectively, for the binary and the multiclass classifications. Omitting the UMAP step led to improved predictive accuracies (96.14% and 85.06%, respectively). As expected, the HC class was distinguished with the highest accuracy. The different classes displayed a tendency to form distinct clusters in the 3D space based on their disease state.

conclusionUrinary peptide data present an effective basis for CKD aetiology differentiation using machine learning models. Although adding the UMAP step to the models did not improve prediction accuracy, it may provide a unique visualization advantage. Additional studies are warranted to further validate the pipeline's clinical potential as well as to expand it to other CKD aetiologies and also other diseases.

Indexed as

Glomerulonephritis, IGARenal Insufficiency, ChronicVasculitisArtificial IntelligenceBiomarkersDiagnosis, DifferentialHumansLiquid BiopsyPeptidesProteomicsBiomarkersPeptideschronic kidney diseasedifferential diagnosispeptidesUMAPurine

Identifiers

PMID37697716
PMCPMC10899775
OpenAlexW4386623849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.